Tuesday, 22 Oct 2019

TNF inhibitor

Date Typesort descending Title Save
17 Mar 2016 News TNF Inhibitors Increase Perioperative Infection Risk
22 Aug 2017 News It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk
22 Feb 2019 News The Risk of Tuberculosis with TNF Inhibitors
28 Jun 2016 News Cancer Risk Lower with TNF inhibitors in Rheumatoid Arthritis
14 May 2015 News Hepatotoxicity and TNF Inhibitors
02 Jan 2017 News Cautious Optimism for Biosimilars in Rheumatology
03 Aug 2018 News Higher Infection Rates for Infliximab in Psoriasis
18 Aug 2016 News Remicade Patent Infringements Denied: Opens Door for New Biosimilars
05 Jun 2015 News Conventional DMARDs extend TNF inhibitor drug survival in patients with spondyloarthropathies
07 Dec 2017 News Infliximab Does Not Increase Perioperative Infection
09 Feb 2016 News FDA Reviews Celltrion's Remicade Biosimilar Today
02 May 2016 Blog Why Not Just Kick the TNFi Habit?
16 Nov 2015 Blog The Born Again Rheumatoid
08 Aug 2016 Slide of the day Tuberculosis Risk Reduction Measures
29 Feb 2016 Slide of the day How to manage TNFi during surgery
29 Aug 2016 Slide of the day Non-Tuberculous Mycobacterial Infection are Common with TNF Inhibitors
24 Jul 2019 Slide of the day anti-TNF Biosimilars in USA
15 May 2017 Slide of the day New TNF Inhibitor Biosimilars
31 Oct 2016 Slide of the day 3 New TNF Inhibitor Biosimilars Approved in 2016
06 Feb 2019 Social The EMAs CHMP has issued a eceived a positive opinion for 2 TNF inhibitor biosimilars: Idacio (adalimumab) and Kromeya (adalimumab). For the treatment of select inflammatory and autoimmune disorders https://t.co/lz7EvtTcTB